BioAtla (BCAB) to Release Earnings on Thursday

BioAtla (NASDAQ:BCAB) is set to release its earnings data after the market closes on Thursday, November 7th. Analysts expect BioAtla to post earnings of ($0.34) per share for the quarter. Persons that wish to register for the company’s earnings conference call can do so using this link.

BioAtla (NASDAQ:BCAB) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.44) EPS for the quarter, beating the consensus estimate of ($0.45) by $0.01. During the same quarter in the prior year, the company earned ($0.75) EPS. On average, analysts expect BioAtla to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

BioAtla Price Performance

Shares of BCAB stock opened at $2.07 on Wednesday. The company has a market capitalization of $100.06 million, a price-to-earnings ratio of -0.95 and a beta of 1.03. BioAtla has a one year low of $1.14 and a one year high of $4.02. The company’s fifty day moving average price is $1.87 and its 200-day moving average price is $1.89.

Analyst Upgrades and Downgrades

Separately, JMP Securities restated a “market outperform” rating and set a $5.00 price objective on shares of BioAtla in a research report on Monday, September 16th.

About BioAtla

BioAtla, Inc, a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck.